Literature DB >> 20680526

Novel targets for treatment of adult acute lymphocytic leukemia.

Margaret T Kasner1.   

Abstract

The treatment of acute lymphocytic leukemia (ALL) results in long-term disease-free survival in only 30-40% of adults. Conventional chemotherapy is toxic and woefully ineffective. Therefore, novel agents are being investigated. Among these agents are monoclonal antibodies such as rituximab, epratuzumab, and alemtuzumab and targeted therapies such as tyrosine kinase inhibitors, mTOR inhibitors, and mitogen-activated protein kinase (MEK) inhibitors. This article discusses such novel targets for the treatment of ALL.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20680526     DOI： 10.1007/s11899-010-0064-8

Source DB:  PubMed          Journal:  Curr Hematol Malig Rep        ISSN： 1558-8211            Impact factor:   4.213


  38 in total

1.  Differentially regulated expression and function of CD22 in activated B-1 and B-2 lymphocytes.

Authors:  Frédéric Lajaunias; Lars Nitschke; Thomas Moll; Eduardo Martinez-Soria; Isabelle Semac; Yves Chicheportiche; R Michael E Parkhouse; Shozo Izui
Journal:  J Immunol       Date:  2002-06-15       Impact factor: 5.422

Review 2.  The TOR pathway: a target for cancer therapy.

Authors:  Mary-Ann Bjornsti; Peter J Houghton
Journal:  Nat Rev Cancer       Date:  2004-05       Impact factor: 60.716

3.  Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia.

Authors:  Andrew P Weng; Adolfo A Ferrando; Woojoong Lee; John P Morris; Lewis B Silverman; Cheryll Sanchez-Irizarry; Stephen C Blacklow; A Thomas Look; Jon C Aster
Journal:  Science       Date:  2004-10-08       Impact factor: 47.728

4.  Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.

Authors:  Deborah A Thomas; Stefan Faderl; Susan O'Brien; Carlos Bueso-Ramos; Jorge Cortes; Guillermo Garcia-Manero; Francis J Giles; Srdan Verstovsek; William G Wierda; Sherry A Pierce; Jianqin Shan; Mark Brandt; Fredrick B Hagemeister; Michael J Keating; Fernando Cabanillas; Hagop Kantarjian
Journal:  Cancer       Date:  2006-04-01       Impact factor: 6.860

5.  A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL).

Authors:  Chadi Nabhan; David Patton; Leo I Gordon; Mary B Riley; Timothy Kuzel; Martin S Tallman; Steven T Rosen
Journal:  Leuk Lymphoma       Date:  2004-11

6.  Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling.

Authors:  Valerie I Brown; Junjie Fang; Keith Alcorn; Rosalind Barr; Jenny M Kim; Robert Wasserman; Stephan A Grupp
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-01       Impact factor: 11.205

Review 7.  CCI-779 Wyeth.

Authors:  Laurie Elit
Journal:  Curr Opin Investig Drugs       Date:  2002-08

8.  In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia.

Authors:  Kim De Keersmaecker; Idoya Lahortiga; Nicole Mentens; Cedric Folens; Leander Van Neste; Sofie Bekaert; Peter Vandenberghe; Maria D Odero; Peter Marynen; Jan Cools
Journal:  Haematologica       Date:  2008-03-05       Impact factor: 9.941

9.  Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study.

Authors:  Adele K Fielding; Susan M Richards; Rajesh Chopra; Hillard M Lazarus; Mark R Litzow; Georgina Buck; I Jill Durrant; Selina M Luger; David I Marks; Ian M Franklin; Andrew K McMillan; Martin S Tallman; Jacob M Rowe; Anthony H Goldstone
Journal:  Blood       Date:  2006-10-10       Impact factor: 22.113

10.  Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia.

Authors:  Pedro J Real; Valeria Tosello; Teresa Palomero; Mireia Castillo; Eva Hernando; Elisa de Stanchina; Maria Luisa Sulis; Kelly Barnes; Catherine Sawai; Irene Homminga; Jules Meijerink; Iannis Aifantis; Giuseppe Basso; Carlos Cordon-Cardo; Walden Ai; Adolfo Ferrando
Journal:  Nat Med       Date:  2008-12-21       Impact factor: 53.440
View more
  2 in total

1.  Adult B-cell acute lymphoblastic leukemia cells display decreased PTEN activity and constitutive hyperactivation of PI3K/Akt pathway despite high PTEN protein levels.

Authors:  A Margarida Gomes; Maria V D Soares; Patrícia Ribeiro; Joana Caldas; Vanda Póvoa; Leila R Martins; Alice Melão; Ana Serra-Caetano; Aida B de Sousa; João F Lacerda; João T Barata
Journal:  Haematologica       Date:  2014-02-21       Impact factor: 9.941

Review 2.  Target Therapy in Hematological Malignances: New Monoclonal Antibodies.

Authors:  Monika Podhorecka; Justyna Markowicz; Agnieszka Szymczyk; Johannes Pawlowski
Journal:  Int Sch Res Notices       Date:  2014-10-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.